ArticleActa oncologica (Stockholm, Sweden)2025

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Alexander Decruyenaere et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.